UY28734A1 - Compuestos de quinolina sustituidos - Google Patents
Compuestos de quinolina sustituidosInfo
- Publication number
- UY28734A1 UY28734A1 UY28734A UY28734A UY28734A1 UY 28734 A1 UY28734 A1 UY 28734A1 UY 28734 A UY28734 A UY 28734A UY 28734 A UY28734 A UY 28734A UY 28734 A1 UY28734 A1 UY 28734A1
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- substituted quinoline
- quinoline compounds
- compositions
- mtp
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000018616 Apolipoproteins B Human genes 0.000 abstract 1
- 108010027006 Apolipoproteins B Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
Esta invención se refiere a inhibidores de la secreción de MTP/Apo-Bde Fórmula (I) donde R1-R7, X1, m y n son como se han definido en la memoria descriptiva, así como a composiciones farmacéuticas que comprenden los compuestos, y a procedimientos de uso de lso compuestos y composiciones. Los compuestos de la invención son útiles en el tratamiento de la obesidad y enfermedades, afecciones o trastornos asociados.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54167804P | 2004-02-04 | 2004-02-04 | |
| US63376304P | 2004-12-06 | 2004-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY28734A1 true UY28734A1 (es) | 2005-09-30 |
Family
ID=34890449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY28734A UY28734A1 (es) | 2004-02-04 | 2005-02-02 | Compuestos de quinolina sustituidos |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US7468378B2 (es) |
| EP (1) | EP1716137A1 (es) |
| JP (1) | JP2007520543A (es) |
| KR (1) | KR100799802B1 (es) |
| AP (1) | AP2006003685A0 (es) |
| AR (1) | AR047529A1 (es) |
| AU (1) | AU2005214159A1 (es) |
| BR (1) | BRPI0507462A (es) |
| CA (1) | CA2555133A1 (es) |
| CO (1) | CO5700721A2 (es) |
| CR (1) | CR8544A (es) |
| EA (1) | EA010369B1 (es) |
| EC (1) | ECSP066717A (es) |
| GE (1) | GEP20084360B (es) |
| IL (2) | IL176715A0 (es) |
| MA (1) | MA28347A1 (es) |
| NL (1) | NL1028192C2 (es) |
| NO (1) | NO20063928L (es) |
| OA (1) | OA13365A (es) |
| PA (1) | PA8623001A1 (es) |
| PE (1) | PE20050773A1 (es) |
| SV (1) | SV2007002007A (es) |
| TW (2) | TWI306454B (es) |
| UY (1) | UY28734A1 (es) |
| WO (1) | WO2005080373A1 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE551339T1 (de) | 2003-11-05 | 2012-04-15 | Sarcode Bioscience Inc | Modulatoren der zellulären adhäsion |
| WO2005080373A1 (en) * | 2004-02-04 | 2005-09-01 | Pfizer Products Inc. | Substituted quinoline compounds |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| US20070203139A1 (en) * | 2004-04-14 | 2007-08-30 | Astrazeneca Ab | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| GEP20104878B (en) | 2005-04-19 | 2010-01-11 | Surface Logix Inc | Inhibitors of microsomal triglyceride transfer protein and apo-b secretion |
| EP2222631B1 (en) * | 2006-10-23 | 2011-08-17 | Pfizer Inc. | Substituted phenylmethyl bicyclocarboxyamide compounds |
| EP2084127A1 (en) | 2006-11-13 | 2009-08-05 | Pfizer Products Inc. | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof |
| WO2008097471A1 (en) * | 2007-02-02 | 2008-08-14 | Shivvers Steve D | High efficiency drier with multi stage heating and drying zones |
| WO2008100423A1 (en) * | 2007-02-09 | 2008-08-21 | Sirtris Pharmaceuticals, Inc. | Gut microsomal triglyceride transport protein inhibitors |
| WO2009014674A1 (en) * | 2007-07-23 | 2009-01-29 | Sirtris Pharmaceuticals, Inc. | Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors |
| ES2748136T3 (es) | 2007-10-15 | 2020-03-13 | United Animal Health Inc | Método para aumentar el rendimiento de las crías |
| ES2830024T3 (es) * | 2007-10-19 | 2021-06-02 | Novartis Ag | Composiciones y métodos para el tratamiento del edema macular |
| WO2010018547A1 (en) * | 2008-08-13 | 2010-02-18 | Pfizer Inc. | Aminoquinoline compounds |
| EP2723717A2 (en) | 2011-06-24 | 2014-04-30 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| MX2013015058A (es) | 2011-06-24 | 2014-01-20 | Amgen Inc | Antagonistas de melastatina 8 de potencial receptor transitorio y su uso en tratamientos. |
| BR112014002675A2 (pt) * | 2011-08-04 | 2017-02-21 | Array Biopharma Inc | "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição" |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| WO2015121877A2 (en) * | 2014-02-17 | 2015-08-20 | Hetero Research Foundation | Polymorphs of lomitapide and its salts |
| PT3203840T (pt) | 2014-10-06 | 2020-10-27 | Vertex Pharma | Moduladores do regulador da condutância transmembranar da fibrose quística |
| US10138206B2 (en) | 2014-10-09 | 2018-11-27 | Glenmark Pharmaceuticals Limited | Amorphous form of lomitapide mesylate |
| US10738030B2 (en) | 2016-03-31 | 2020-08-11 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| LT3519401T (lt) | 2016-09-30 | 2021-11-25 | Vertex Pharmaceuticals Incorporated | Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas |
| MX2021013639A (es) | 2016-12-09 | 2022-09-30 | Vertex Pharma | Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística. |
| CA3066084A1 (en) | 2017-06-08 | 2018-12-13 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| EP3640242B1 (en) * | 2017-06-16 | 2023-04-19 | Hitgen Ltd. | Rock-inhibiting compound and uses thereof |
| AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CN111051280B (zh) | 2017-08-02 | 2023-12-22 | 弗特克斯药品有限公司 | 制备吡咯烷化合物的方法 |
| TWI719349B (zh) | 2017-10-19 | 2021-02-21 | 美商維泰克斯製藥公司 | Ｃｆｔｒ調節劑之結晶形式及組合物 |
| MA51039A (fr) | 2017-12-08 | 2020-10-14 | Vertex Pharma | Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2819039A1 (de) | 1978-04-29 | 1979-11-08 | Bayer Ag | Leimungsmittel fuer papier |
| DK104382A (da) | 1981-03-11 | 1982-09-12 | Wellcome Found | Fremgangsmaade til fremstilling af substituerede biphenylforbindelser |
| JP2527107B2 (ja) | 1991-04-16 | 1996-08-21 | 日本新薬株式会社 | 固体分散体の製造方法 |
| CA2091102C (en) | 1992-03-06 | 2009-05-26 | John R. Ii Wetterau | Microsomal triglyceride transfer protein |
| US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| CA2191352C (en) | 1994-05-27 | 2001-01-30 | Carlo Farina | Quinoline derivatives as tachykinin nk3 receptor antagonists |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| DE19519245C2 (de) * | 1995-04-14 | 2003-04-30 | Boehringer Ingelheim Kg | Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| EP0832069B1 (en) | 1995-06-07 | 2003-03-05 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
| DK0832069T3 (da) | 1995-06-07 | 2003-04-22 | Pfizer | Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B) |
| US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| KR20000065219A (ko) * | 1996-05-20 | 2000-11-06 | 마르크 젠너 | 티엔에프 저해제 및 피디이-4 저해제로서의 퀴놀린 카르복사미드 |
| IL121203A (en) | 1996-07-01 | 2001-04-30 | Lilly Co Eli | 1, 2, 3, 4-tetrahydroisoquinidines, process for their preparation and pharmaceutical compositions containing the same for treating hyperglycemia and hyperlipidemia |
| KR100217618B1 (ko) * | 1996-12-12 | 1999-09-01 | 정몽규 | 와셔액 분사위치 조절 장치 |
| WO1998027979A1 (en) | 1996-12-20 | 1998-07-02 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of microsomal triglyceride transfer protein and method |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| US5968950A (en) | 1997-06-23 | 1999-10-19 | Pfizer Inc | Apo B-secretion/MTP inhibitor hydrochloride salt |
| ATE364374T1 (de) | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| AP1201A (en) | 1997-09-17 | 2003-09-01 | Smithkline Beecham Corp | Method for the synthesis of quinoline derivatives. |
| JP2001526265A (ja) * | 1997-12-22 | 2001-12-18 | ファルマシア・アンド・アップジョン・カンパニー | 抗ウイルス剤としての４−ヒドロキシキノリン−３−カルボキサミドおよびヒドラジド |
| CO5090829A1 (es) | 1998-07-21 | 2001-10-30 | Novartis Ag | Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b. |
| CA2325358C (en) | 1999-11-10 | 2005-08-02 | Pfizer Products Inc. | 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b |
| CO5271688A1 (es) | 1999-11-10 | 2003-04-30 | Pfizer Prod Inc | Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales |
| US20020032238A1 (en) * | 2000-07-08 | 2002-03-14 | Henning Priepke | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments |
| US6417367B1 (en) * | 2000-08-11 | 2002-07-09 | Pfizer Inc. | Methods of making quinoline amides |
| MXPA03003002A (es) | 2000-10-05 | 2004-12-06 | Fujisawa Pharmaceutical Co | Compuestos de benzamina como inhibidores de la secrecion de la apo b. |
| SI1404653T1 (sl) | 2001-06-28 | 2008-12-31 | Pfizer Prod Inc | S triamidom substituirani indoli, benzofurani in benzotiofeni kot zaviralci mikrosomske prenašalnebeljakovine za trigliceride (MTP) in/ali izločanja apolipoproteina B (APO B) |
| SK2242004A3 (en) * | 2001-10-25 | 2004-11-03 | Takeda Chemical Industries Ltd | Quinoline compound |
| US20030162758A1 (en) * | 2001-12-07 | 2003-08-28 | Schwartz Daniel M. | Treatment for age-related macular degeneration (AMD) |
| US20030162788A1 (en) * | 2002-01-10 | 2003-08-28 | Boehringer Ingelheim Pharma Kg | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals |
| CN101838218A (zh) | 2002-02-28 | 2010-09-22 | 日本烟草产业株式会社 | 酯化合物及其医药用途 |
| WO2004056775A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Microsomal triglyceride transfer protein inhibitors |
| CA2505604A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Microsomal triglyceride transfer protein inhibitors |
| WO2005080373A1 (en) * | 2004-02-04 | 2005-09-01 | Pfizer Products Inc. | Substituted quinoline compounds |
-
2005
- 2005-01-24 WO PCT/IB2005/000167 patent/WO2005080373A1/en not_active Ceased
- 2005-01-24 EA EA200601239A patent/EA010369B1/ru not_active IP Right Cessation
- 2005-01-24 AU AU2005214159A patent/AU2005214159A1/en not_active Abandoned
- 2005-01-24 JP JP2006551942A patent/JP2007520543A/ja active Pending
- 2005-01-24 GE GEAP20059563A patent/GEP20084360B/en unknown
- 2005-01-24 AP AP2006003685A patent/AP2006003685A0/xx unknown
- 2005-01-24 KR KR1020067015770A patent/KR100799802B1/ko not_active Expired - Fee Related
- 2005-01-24 OA OA1200600247A patent/OA13365A/en unknown
- 2005-01-24 EP EP05702327A patent/EP1716137A1/en not_active Withdrawn
- 2005-01-24 BR BRPI0507462-2A patent/BRPI0507462A/pt not_active IP Right Cessation
- 2005-01-24 CA CA002555133A patent/CA2555133A1/en not_active Abandoned
- 2005-02-02 UY UY28734A patent/UY28734A1/es unknown
- 2005-02-02 PE PE2005000125A patent/PE20050773A1/es not_active Application Discontinuation
- 2005-02-02 AR ARP050100394A patent/AR047529A1/es not_active Application Discontinuation
- 2005-02-03 US US11/049,852 patent/US7468378B2/en not_active Expired - Fee Related
- 2005-02-03 TW TW094103301A patent/TWI306454B/zh not_active IP Right Cessation
- 2005-02-03 TW TW097141214A patent/TW200906800A/zh unknown
- 2005-02-04 PA PA20058623001A patent/PA8623001A1/es unknown
- 2005-02-04 NL NL1028192A patent/NL1028192C2/nl not_active IP Right Cessation
- 2005-02-04 SV SV2005002007A patent/SV2007002007A/es not_active Application Discontinuation
-
2006
- 2006-06-15 US US11/424,488 patent/US7368573B2/en not_active Expired - Fee Related
- 2006-07-05 IL IL176715A patent/IL176715A0/en unknown
- 2006-07-21 EC EC2006006717A patent/ECSP066717A/es unknown
- 2006-07-28 CO CO06074303A patent/CO5700721A2/es not_active Application Discontinuation
- 2006-08-03 CR CR8544A patent/CR8544A/es not_active Application Discontinuation
- 2006-08-04 MA MA29241A patent/MA28347A1/fr unknown
- 2006-09-01 NO NO20063928A patent/NO20063928L/no not_active Application Discontinuation
- 2006-10-30 US US11/554,351 patent/US7393958B2/en not_active Expired - Fee Related
-
2010
- 2010-10-27 IL IL208963A patent/IL208963A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28734A1 (es) | Compuestos de quinolina sustituidos | |
| ECSP088329A (es) | Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8 | |
| CR9834A (es) | [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la ezquizofrenia | |
| CY1109998T1 (el) | Ενδυναμωτες υποδοχεων γλουταμινικου | |
| GT200500363A (es) | 3-amino-pirazol [3,4b] piridinas con inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento. | |
| CR8649A (es) | Derivados de formamidina para el tratamiento de enfermedades | |
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| SV2005001973A (es) | Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500) | |
| ECSP077188A (es) | Un uso de sulfonanilidas como fungicidas agrícolas y hortícolas | |
| CR9034A (es) | Preparacion y uso de derivados de acido bifenil-4-il-carbonilamino para el tratamiento de la obesidad | |
| CR10060A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
| ECSP067121A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
| ECSP077296A (es) | Fenilaminotiazoles sustituidos y su uso | |
| CR10304A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
| ECSP067120A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
| ECSP055964A (es) | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 | |
| CR10497A (es) | Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38 | |
| CR11423A (es) | NUEVOS INHIBIDORES DE sEH Y SU USO | |
| UY29149A1 (es) | Tiazolil-dihidro-indazoles | |
| UY28945A1 (es) | Derivados de pirrolopiridina | |
| CR9182A (es) | Derivado de quinolina, su uso, preparacion y medicamento que lo contiene | |
| DOP2006000017A (es) | Pirazolopiridinas y sales de las mismas, una composición farmaceútica que comprende dichos compuestos, un método para prepararlos y su uso | |
| DOP2006000024A (es) | Tiazolidinonas, su preparación y su uso como medicamento | |
| BRPI0515725A (pt) | piridinuréias de nicotinamida como inibidoras de cinase de receptor do fator de crescimento endotelial vascular (vegf) | |
| HN2003000104A (es) | Derivados de ciclopenteno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DESI | Application deemed to be withdrawn |
Effective date: 20140310 |